Jean-Pierre Bayley

List of Publications by Citations

32 papers	1,976 citations	18 h-index	34 g-index
34 ext. papers	2,230 ext. citations	6.7 avg, IF	4.54 L-index

#	Paper	IF	Citations
32	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncology, The*, **2009**, 10, 764-71	21.7	405
31	SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. *Lancet Oncology, The*, **2010**, 11, 366-72	21.7	227
30	The Warburg effect in 2012. *Current Opinion in Oncology*, **2012**, 24, 62-7	4.2	145
29	The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. *BMC Medical Genetics*, **2005**, 6, 39	2.1	142
28	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. *Nature Reviews Endocrinology*, **2017**, 13, 233-247	15.2	140
27	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. *BMC Medical Genetics*, **2008**, 9, 20	2.1	115
26	Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. *Molecular Cancer*, **2009**, 8, 89	42.1	102
25	Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. *Current Opinion in Genetics and Development*, **2010**, 20, 324-9	4.9	94
24	The role of complex II in disease. *Biochimica Et Biophysica Acta - Bioenergetics*, **2013**, 1827, 543-51	4.6	88
23	Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. *BMC Medical Genetics*, **2006**, 7, 1	2.1	86
22	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. *Oncotarget*, **2015**, 6, 38777-88	3.3	65
21	Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1386-93	5.6	55
20	Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. *Familial Cancer*, **2011**, 10, 355-63	3	51
19	Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. *PLoS ONE*, **2009**, 4, e7987	3.7	40
18	Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. *BMC Medical Genetics*, **2014**, 15, 111	2.1	33
17	The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients. *BMC Medical Genetics*, **2009**, 10, 34	2.1	32
16	The phenotype of germline mutation carriers: a nationwide study. *European Journal of Endocrinology*, **2017**, 177, 115-125	6.5	27

15	The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. *European Journal of Human Genetics*, **2010**, 18, 62-6	5.3	25
14	Models of parent-of-origin tumorigenesis in hereditary paraganglioma. *Seminars in Cell and Developmental Biology*, **2015**, 43, 117-124	7.5	17
13	Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients. *Endocrine-Related Cancer*, **2009**, 16, 929-37	5.7	14
12	Allele-specific expression of the IL-1 alpha gene in human CD4+ T cell clones. *Journal of Immunology* , **2003**, 171, 2349-53	5.3	13
11	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. *Oncotarget*, **2017**, 8, 14525-14536	3.3	13
10	Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers. *Human Molecular Genetics*, **2016**, 25, 3715-3728	5.6	11
9	Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma. *Journal of Medical Genetics*, **2020**, 57, 96-103	5.8	8
8	No evidence for increased mortality in SDHD variant carriers compared with the general population. *European Journal of Human Genetics*, **2015**, 23, 1713-6	5.3	7
7	Analysis of allelic expression patterns of IL-2, IL-3, IL-4, and IL-13 in human CD4+ T cell clones. *European Journal of Immunology*, **2003**, 33, 2142-8	6.1	7
6	Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. *European Journal of Human Genetics*, **2018**, 26, 1339-1347	5.3	6
5	Mathematical Models for Tumor Growth and the Reduction of Overtreatment. *Journal of Neurological Surgery, Part B: Skull Base*, **2019**, 80, 72-78	1.5	4
4	Advances in paraganglioma-pheochromocytoma cell lines and xenografts. *Endocrine-Related Cancer* , **2020**, 27, R433-R450	5.7	2
3	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 459-471	5.6	1
2	International initiative for a curated variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma. *Journal of Medical Genetics*, **2021**,	5.8	1
1	Are these compound heterozygous mutations of SDHB really mutations?. *Pediatric Blood and Cancer*, **2010**, 55, 211; author reply 212	3	